Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 135 participants.

Also called NCT05140694

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 135 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05140694
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05140694. Randomized; double masking; primary purpose treatment. Start 2023-12-01 (anticipated); primary completion 2024-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
Condition
Metabolic-associated Fatty Liver Disease
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Empagliflozin and Dulaglutide
Lead sponsor
Seoul National University Bundang Hospital (class: other)

Record details

Record id
cardio:ct-nct05140694
Content hash
32c9d82832e2fe03d9658c5419a922efe920faea3600e67bfe5d1a59239ab8e1